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Summary. Samples of 38 human renal cell carcinomas 
(RCC) were subjected to routine histopathological ex m- 
ination but also to in vitro sensitivity testing with mito- 
mycin C, vinblastine and interferon Alpha-2a at various 
concentrations corresponding to serum titers recom- 
mended to be effective in vivo, employing a monolayer 
assay. Extending earlier in vitro studies, both tumor cell 
kill rates (TCKR) and proliferation rates (PR) were 
assessed. Following in vitro preparation the tumor cell 
cultures were simultaneously exposed to the anticancer 
drugs listed above. The proliferation rates were deter- 
mined immunocytochemically using the monoclonal anti- 
body Ki-67. Nine (23.7%) of the tumors investigated 
revealed temporary and limited response with respect o 
either TCKR or PR. Improvement of this percentage 
could only be obtained by increasing drug concentration 
to titers with toxicity intolerable for in vivo administrat- 
ion. The in vivo data presented correspond to clinical 
temporary and limited remissions in patients with metas- 
tatic RCC ranging up to 25 %. 
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Approximately 30% of patients have metastases at the 
time renal cell carcinoma (RCC) is diagnosed [15]. 
Conventional modern management of advanced solid 
tumors applies cytotoxic agents. Despite the remarkable 
advances achieved in other tumors, RCC has remained 
unmanageable by these agents. Numerous drugs have 
been administered assingle agents predominantly vinblas- 
tine nowadays [2, 3]. Hrushesky and Murphy reported a
25 % objective response, superior to any other single agent 
or combination therapy [ 14], which was also confirmed by 
other investigators [3, 13]. The interferons represent 
glycoproteins produced by human cells in response to 
viral infections as well as various other inducers. The 
antiviral and antineoplastic activity is mediated either by 
direkt or indirect umor cytotoxicity via natural killer cell 
stimulation or both (10, 20, 24). Complete and partial 
remission rates ranging from 20 %-25 % have been report- 
ed for patients with lung metastases of RCC treated with 
interferon-alpha, while patients with bone metastases 
showed nearly noresponse to this treatment [2, 3, 5, 6, 21]. 
RCC is a pleomorphic malignoma [17]. To detect he 
biological behavior of renal tumor cells under treatment 
we studied 38 different human RCCs in vitro, exposing 
them to different cytotoxic agents such as mitomycin, 
vinblastine and interferon-alpha-2a. Cell response under 
treatment was assessed by determining the tumorcell kill 
rate (TCKR) and the proliferation rate (PR) 
Material and methods 
Tumor tissue of 38 patients with RCC was prepared and analyzed. 
According to the method recently described [16] the procedure of 
cell preparation was chosen as follows: 
Tumors from previously untreated patients were obtained by 
conventional tumor nephrectomy, and a macroscopically homogen- 
ous area lacking fibrosis, necrosis, or hem rrhage was excised for 
preparation. Figure 1 exhibits the tumorcell preparation schemati- 
cally. 
One sample ofthe excised tumor tissue was taken for in vitro cell 
preparation, another sample for histological examination as a 
"reference slide." In earlier investigations this procedure has been 
proved to produce pure tumor cell cultures, employing cytogenetic 
[16] and immunocytochemical methods [22]. 
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Fig. l. Preparation of malignant renal cells for in vitro drug 
sensitivity testing 
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24h and grew out to an almost confluent monolayer, in most cases 
within 3-7 days after seeding. 
Fig. 2. The 25 cm 3 flask for cell culturing, the 24-well multiplate and 
the "Thermanox" platelets which can be attached to conventional 
glass slides 
Table l. Drug concentrations used for RCC in vitro sensitivity 
testing 
Drug Single concentration a 
Mitomycin C 0.50 ~tg/ml 
Vinblastine 0.15 gg/ml 
Interferon alpha-2a 30 U/ml 
RCC, renal cell carcinoma 
a Based on the recommended therapeutic serum (in vivo) concentra- 
tions, the drugs were tested in single, double, five- and tenfold 
concentrations; Interferon alpha-2a was additionally tested in 20- 
fold concentration 
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Fig. 3. Immunocytochemical l beling using the monoclonal anti- 
body Ki-67 and the alkaline phosphatase antialkaline phosphatase 
complex. AP, alkaline phosphatase 
Preparation of primary cell cultures 
After mechanical nd enzymatic reatment the tissue fragments were 
centrifuged and washed twice in RPMI 1640 medium. Subsequently 
the tissue clusters were resuspended in a centrifuge tube containing 
2-4ml culture medium (RPMI 1640 supplemented with 15% fetal 
calf serum and 1% penicillin) and dispersed vigorously by means of a 
Pasteur pipette. The suspension sedimented for 1 min and the 
supernatant containing over 90% of single cells with low viability 
and cell debris was decanted. The pellet consisting of over 90% of 
small cell clusters with approximately 10-15 cells was resuspended 
and seeded in culture. The cell clusters were incubated at 37~ in a 
humidified atmosphere containing 5 % CO2 in 25 cm 2 Falcon flasks 
(BIOCHROM, 1000Berlin, FRG), each flask containing 5ml of 
culture medium. The small cell clusters attached to the flasks within 
Preparation of in vitro slides 
After decanting the medium of the primary cultures, the cells were 
washed twice with warm (37~ trypsin to remove cell debris and 
remaining blood cells. One part of the cell clusters were transferred 
to another culture flask for further subculturing processes, the other 
part was pipetted equally into 24-well multiplates containing 3ml 
culture medium without any antibiotics and each well was equipped 
with one plastic platelet (Thermanox, NUNC, 6200Wiesbaden, 
FRG). This efficient echnique, developed in Hannover, increases 
the amount of cells on slides, thus diminishing the loss of material, 
because cells grow much better on the rougher surface of plastic than 
on glass (Fig. 2). 
In 3-7 days after the first cell passage the untreated cells had 
grown to a confluent monolayer, which has considered the starting 
point for evaluation of the treated and untreated cells on the 
platelets. The cells either were fixed in acetone or chloreform (for 
immunohistochemical staining [7]) and subsequently attached to 
conventional glass slides by using a special adhesive (LOCTITE 
Comp., FRG). Finally staining was performed as described. 
Short-term in vitro sensitivity testing 
Within the logarithmic cell growing phase the culture medium of the 
24-well multiplates was changed, administering the therapeutic 
agents (mitomycin, vinblastine, interferon alpha-2a) in different 
doses. In Table 1 the single drug concentrations transferred from in 
vivo to in vitro conditions according to Hamburger and Salmon are 
outlined [11]. Only single drugs, not multiple drugs were adminis- 
tered to the tumor cell suspensions. The drugs were tested in single, 
two-, five- and tenfold concentrations. In addition interferon alpha- 
2a was tested in 20-fold concentration (equivalent to 100 X 106 U/  
1.75m 2 in vivo). For each tumor two culture wells with no 
administration oftherapeutic agents (control group) and two culture 
wells per tested drug concentration were used. The platelets were 
taken for immunocytochemical determination of the PR with the 
monoclonal antibody Ki-67 [7] (DIANOVA, 2000 Hamburg, FRG). 
There were 28 platelets per each prepared tumor. 
On the average, the platelet surfaces of the control groups were 
fully covered with tumor cells within 2-4 days after cell passage. This 
was considered the starting point for cell counting to obtain the 
TCKR comparing the number of treated cells with that of untreated 
cells [23]. 
Gerdes and coworkers made available the monoclonal antibody 
Ki-67, which binds to a human nuclear antigen associated with cell 
proliferation [8]. Cell cycle analysis demonstrated that the nuclear 
antigen detected by Ki-67 is expressed only in the G1, S, G2, and M 
phases of proliferating cells regardless of whether a tumor is 
malignant, but is absent in GO cells [9]. The Ki-67 assay thereby 
established an easy, fast, and reproducible method of determining 
the growth fractions of tumor in situ. 
According to Gerdes [7] 200 cells in four different areas of each 
specimen were counted to measure the proportion of Ki-67-positive 
cells. The technique for immunocytochemical staining was first 
described by Gerdes in 1985 [7] and is presented schematically in
Fig. 3. The acetone- and cloroform-fixed cells are exposed to the 
monoclonal antibody diluted in RPMI 1640 medium for approxi- 
mately 30 rain. After washing in tris-buffered solution (pH 7.4-7.6), 
the cells are incubated with rabbit antimouse IgG followed by 
exposition to alkaline phosphatase antialkaline phosphatase 
(APAAP) complex after another washing [4]. Subsequently the 
slides are stained with "fast red" and counterstained with hemalum 
[4]. Presence of the specific antigen is indicated by a red instead of 
blue color eaction after counterstaining. 
Table 2. Histological grading and staging of 38 renal cell carcinomas 
tested in vitro for drug sensitivity 
Histological grading and staging n 
G1, pTl-2 8 
G1, pT3-4 2 
G2, pTl-2 5 
G2, pT3-4 12 
G3, pTl-2 4 
G3, pT3-4 7 
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Fig. 4. Average tumor cell kill rates (TCKR) of38 primary renal cell 
tumors tested in vitro under xposure to different concentrations of 
cytostatic agents (mitomycin C, vinblastine) and int rferon Alpha- 
2a 
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Fig. 5. Average reduction of proliferation rates (PR) of 38 primary 
renal tumors tested in vitro under exposure to different concentra- 
tions of cytostatic agents (mitomycin C, vinblastine) and interferon 
Alpha-2a 
Table 3. Histological grading and staging of 38 renal tumors which 
were partially sensitive in the in vitro drug testing 
Grading and staging n TCKR Reduction of 
>50% PR>50% 
G1-2, pT1-2 1 + -- 
G3, pT3-4 3 + -- 
G1-2, pT1-2 3 -- + 
G3, pT3-4 2 -- § 
Total 9 (23.7%) 
TCKR, Tumor cell kill rate; PR, proliferation rate 
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Results 
Table 2 shows the histological grade and stage of all 38 
RCC tested in this study. As demonstrated, not only 
culturing of undifferentiated tumors but also of low-grade 
RCC was successful. 
All the cells of each renal tumor analyzed originated 
from the same primary in vitro cell culture. The PR of each 
untreated and treated group (two wells per group) did not 
differ more than 4% per group. So it can be concluded that 
the investigated cell suspensions exhibited a standardized 
in vitro growth behavior. 
Figure 4 exhibits the TCKR achieved by exposing the 
malignant cells to the various agents (mitomycin, vinblas- 
tine, interferon-alpha-2) in different concentrations corre- 
sponding to the recommended therapeutic serum concen- 
trations in vivo. Figure5 compares the declining PR 
illustrated in Fig. 4 to the PR obtained in the control 
groups. Administering the chemotherapeutics at the low- 
est titers corresponding to recommended serum concen- 
trations in vivo, TCKR over 50 % paralleling reduction of 
the PR were over 50% not observed. Only four (10.5%) of 
the RCC cultures exhibited TCKR over 50% and only five 
(13.2%) a reduction of PR over 50% (Table 3). 
Discussion 
Increasing the efficacy of an individual chemotherapeutic 
agent while preventing or minimizing its inherent side 
effects remains an unsolved enigma in the treatment of 
patients with advanced RCC. In 1977 Hamburger and 
Salmon [11] introduced an in vitro soft agar system called 
the human tumor cloning assay (HTCA). To a certain 
extent this approach proved applicable in predicting 
response or resistance of a given tumor in vivo with regard 
to chemotherapy as attested to by various clinical studies 
[1, 12, 18, 25]. In recent reviews the overall predictive 
accuracy was estimated to be 50%-70% for in vivo 
sensitivity and 91%-96% for in vivo resistance [12, 18, 
25]. 
According to these data, in more than one third of the 
cases a tumor has to be considered insensitive to a 
chemotherapeutic agent though tested to be so in vitro. 
However, with regard to resistance a highly reliable 
correlation between in vitro and in vivo results (more than 
90%) can be expected. 
The success rate of colony formation in vitro for RCC 
averages 50%, as reported recently [12, 25]. During past 
years in vitro cell preparation methods have been im- 
proved, applying mechanical and enzymatic techniques. 
The monolayer procedure according to Kovacs et al. [16] 
provides an in vitro success rate for RCC of nearly 90%. 
For routine application this method proved valuable in 
producing slides with high cell density, and additionally 
preserves material and cells [23], thus allowing simul- 
taneous assays to be performed which are particularily 
suitable for in vitro drug sensitivity studies as presented 
herein. Reliable interpretation of tumor cell cultures 
essentially depends on the positive identification of malig- 
nancy and the purity of the tumor cell population as well 
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[12, 22]. For the in vitro cell preparation technique 
presented here this was confirmed by additional cytoge- 
netic and immunocytochemical  analyses as reported earli- 
er [ 16, 22]. 
Metastatic RCC is a malignancy resistant o conven- 
tional chemotherapy [3, 13, 15]. Comparing the drugs 
which demonstrated at least slight therapeutic efficacy 
mitomycin and vinblastine are considered superior ac- 
cording to combined in vitro/in vivo studies [12, 25]. The 
in vivo response rates reported for these agents range 
between 10 %-20 % [3, 13, 15], evidencing the need for new 
chemo- as well as immunotherapeutic effective strategies. 
The latter seen promising since in RCC immunologic 
interactions appear to enhance therapeutic response [3]. 
In this context, according to preliminary studies inter- 
feron is suggested to be active due both to its indirect and 
direct antineoplastic effect [3, 19]. This prompted our 
interest o comparatively assess the therapeutic efficacy of  
mitomycin C, vinblastine, and interferon by simultaneous 
in vitro testing. The data obtained in this study revealed 
that none of these substances as claimed as anticancer 
drugs was able to achieve a TCKR along with simul- 
taneous reduction of  the PR of more than 50% each. 
Administering the drugs at the lowest concentrations 
corresponding to the recommended therapeutic serum 
titers in vivo, 9 of  the 38 RCC (23.7%) exhibited either 
TCKR over 50% or a reduction of PR over 50%. 
Transferring these results to in vivo conditions only a 
temporary and limited response in patients uffering from 
the corresponding RCC has to be expected, followed by 
tumor progression, considering the highly malignant cell 
clones resistant o any therapeutic measure. Recent stu- 
dies on in vitro sensitivity testing only considered TCKR. 
Therefore the immunocytochemical technique for deter- 
mining the PR as developed by Gerdes et al. [7] detects one 
more important aspect of  the complex process of the 
development of therapeutic resistance in vitro. Among the 
drugs tested in this study no significant difference was 
found with respect to therapeutic efficacy. The partial 
response rate of  23.7% obtained in vitro corresponds to 
clinical studies in which temporary and limited remission 
rates were achieved with conventional chemotherapy in
patients suffering from metastatic RCC ranging up to 
25% [2, 3, 5, 6, 13]. Complete remissions, the most 
valuable criterion for judging success or failure of treat- 
ment hardly occur; the percentage does not differ signifi- 
cantly from that of patients with advanced isease who 
only undergo nephrectomy (incidence: 0.5%-4%) [21]. 
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